Objective:To evaluate the efficacy and safety of Oxaliplatin in the patients with colorectal cancer. Methods:In a multicenter randomized control study,a total of 144 patients were divided into four groups:Oxaliplatin(...Objective:To evaluate the efficacy and safety of Oxaliplatin in the patients with colorectal cancer. Methods:In a multicenter randomized control study,a total of 144 patients were divided into four groups:Oxaliplatin(Haitong)+5-FU,CF(group A) 41 cases;5-FU+CF(group B) 41 cases;Oxaliplatin(Haitong)+5-FU,CF(group C) 31 cases;Oxaliplatin(positive drug)+5-FU+CF(group D) 31 cases. Oxaliplatin combination regimen:L-OHP 130 mg/m2 i.v. infusion 2 h d1;CF 200 mg/m2 i.v. 2 h d1-d5;5-FU 300 mg/m2 i.v. infusion 4 h d1-d5(after CF). 5-FU+CF combination regimen:CF 200 mg/m2 i.v. infusion 2 h d1-d5,5-FU 300 mg/m2 i.v. infusion 4h d1-d5(after CF),the schedule was repeated every 3 weeks. The total cycles were 3. Results:After three circles treatment,overall response rate of 4 groups was 24.4%(group A),2.4%(group B),25.8%(group C) and 19.4%(group D),respectively. The response rate was significantly different between group A and group B(P < 0.01),but no significant difference was observed between group C and group D(P > 0.05). Conclusion:The Oxaliplatin(Haitong) for injection combination regimen is effective in the treatment of colorectal cancer.展开更多
OBJECTIVE To study the clinical characteristics and prognostic factors for bronchioloalveolar carcinoma. METHODS Clinical data from 107 inpatient cases at The Cancer Hospital of Tianjin Medical University, from 1990-2...OBJECTIVE To study the clinical characteristics and prognostic factors for bronchioloalveolar carcinoma. METHODS Clinical data from 107 inpatient cases at The Cancer Hospital of Tianjin Medical University, from 1990-2000, were retrospectively reviewed. RESULTS The overall 1, 3 and 5-year survival rates were 88.7, 64.8 and 48.6% respectively. The main prognostic factors were tumor diameter (P= 0.022), bronchial stump (P=0.016), TNM stage (P=0.000), T stage (P= 0.002), N stage (P=0.000) and postoperation radiotherapy (P=0.001). Cox regression analysis suggested that the TNM stage (P=0.000) and tumor diameter (P=0.015) are independent factors affecting the prognosis. CONCLUSION The overall survival rate of BAC patients was superior to those with other non-small cell lung cancer (NSCLC). The TNM stage and tumor diameter were independent factors affecting the prognosis for BAC.展开更多
文摘Objective:To evaluate the efficacy and safety of Oxaliplatin in the patients with colorectal cancer. Methods:In a multicenter randomized control study,a total of 144 patients were divided into four groups:Oxaliplatin(Haitong)+5-FU,CF(group A) 41 cases;5-FU+CF(group B) 41 cases;Oxaliplatin(Haitong)+5-FU,CF(group C) 31 cases;Oxaliplatin(positive drug)+5-FU+CF(group D) 31 cases. Oxaliplatin combination regimen:L-OHP 130 mg/m2 i.v. infusion 2 h d1;CF 200 mg/m2 i.v. 2 h d1-d5;5-FU 300 mg/m2 i.v. infusion 4 h d1-d5(after CF). 5-FU+CF combination regimen:CF 200 mg/m2 i.v. infusion 2 h d1-d5,5-FU 300 mg/m2 i.v. infusion 4h d1-d5(after CF),the schedule was repeated every 3 weeks. The total cycles were 3. Results:After three circles treatment,overall response rate of 4 groups was 24.4%(group A),2.4%(group B),25.8%(group C) and 19.4%(group D),respectively. The response rate was significantly different between group A and group B(P < 0.01),but no significant difference was observed between group C and group D(P > 0.05). Conclusion:The Oxaliplatin(Haitong) for injection combination regimen is effective in the treatment of colorectal cancer.
文摘OBJECTIVE To study the clinical characteristics and prognostic factors for bronchioloalveolar carcinoma. METHODS Clinical data from 107 inpatient cases at The Cancer Hospital of Tianjin Medical University, from 1990-2000, were retrospectively reviewed. RESULTS The overall 1, 3 and 5-year survival rates were 88.7, 64.8 and 48.6% respectively. The main prognostic factors were tumor diameter (P= 0.022), bronchial stump (P=0.016), TNM stage (P=0.000), T stage (P= 0.002), N stage (P=0.000) and postoperation radiotherapy (P=0.001). Cox regression analysis suggested that the TNM stage (P=0.000) and tumor diameter (P=0.015) are independent factors affecting the prognosis. CONCLUSION The overall survival rate of BAC patients was superior to those with other non-small cell lung cancer (NSCLC). The TNM stage and tumor diameter were independent factors affecting the prognosis for BAC.
